Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.

about

Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients.

P2860

Q33838871-A26446BF-5E01-4239-8570-4D5C8E54B193 Q49885166-C8533269-E74E-43E4-AAE9-8D6FC77FD005

P2860

Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.

Item

http://www.wikidata.org/entity/Q36256669

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@ast

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@en

type

Item

label

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@ast

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@en

prefLabel

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@ast

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@en

P1476

Splenic Enlargement and Bone M ...... for Metastatic Breast Cancer.

@en

P2093

Andreas Makris

http://www.w3.org/2001/XMLSchema#string

Anwar R Padhani

http://www.w3.org/2001/XMLSchema#string

David Miles

http://www.w3.org/2001/XMLSchema#string

David Woolf

http://www.w3.org/2001/XMLSchema#string

Michael Kosmin

http://www.w3.org/2001/XMLSchema#string

Noorulhuda Jawad

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

Diffusion magnetic resonance imaging in cancer patient management.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?

P2888

s11523-017-0477-6

P304

229-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0477-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28110417

http://www.w3.org/2001/XMLSchema#string

Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.

about

P2860

P2860

Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698